{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T00:36:35Z","timestamp":1791246995869,"version":"4.1.0"},"reference-count":72,"publisher":"American Society of Hematology","issue":"18","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2021,11,4]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Inborn errors of immunity (IEIs) are rare inherited disorders arising from monogenic germline mutations in genes that\u00a0regulate the immune system. The majority of IEI are primary immunodeficiencies characterized by severe infection often associated with autoimmunity, autoinflammation, and\/or malignancy. Allogeneic hematopoietic stem cell transplant (HSCT) has been the corrective treatment of choice for many IEIs presenting with severe disease in early childhood, and experience has made this a successful and comparatively safe treatment in affected children. Early HSCT outcomes in adults were poor, resulting in extremely limited use worldwide. This is changing because of a combination of improved IEI diagnosis to inform patient selection, better understanding of the natural history of specific IEI, and improvements in transplant practice. Recently published HSCT outcomes for adults with IEIs have been comparable with pediatric data, making HSCT an important option for correction of clinically severe IEIs in adulthood. Here we discuss our practice for patient selection, timing of HSCT, donor selection and conditioning, peri- and post-HSCT management, and our approach to long-term follow-up. We stress the importance of multidisciplinary involvement in the complex decision-making process that we believe is required for successful outcomes in this rapidly emerging area.<\/jats:p>","DOI":"10.1182\/blood.2020008187","type":"journal-article","created":{"date-parts":[[2021,6,2]],"date-time":"2021-06-02T21:03:38Z","timestamp":1622667818000},"page":"1666-1676","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":30,"title":["How I use allogeneic HSCT for adults with inborn errors of immunity"],"prefix":"10.1182","volume":"138","author":[{"given":"Siobhan O.","family":"Burns","sequence":"first","affiliation":[{"name":"Institute of Immunity & Transplantation, University College London, London, United Kingdom;"},{"name":"Department of Immunology, Royal Free London Hospitals NHS Foundation Trust, London, United Kingdom; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4834-1130","authenticated-orcid":false,"given":"Emma C.","family":"Morris","sequence":"additional","affiliation":[{"name":"Institute of Immunity & Transplantation, University College London, London, United Kingdom;"},{"name":"Department of Immunology, Royal Free London Hospitals NHS Foundation Trust, London, United Kingdom; and"},{"name":"Stem Cell Transplant Unit, Department of Haematology, University College London Hospitals NHS Foundation Trust, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"issue":"1","key":"2021110415300390100_B1","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1007\/s10875-020-00758-x","article-title":"Human inborn errors of immunity: 2019 update of the IUIS phenotypical classification","volume":"40","author":"Bousfiha","year":"2020","journal-title":"J Clin Immunol."},{"issue":"13","key":"2021110415300390100_B2","doi-asserted-by":"crossref","first-page":"1989","DOI":"10.1182\/blood-2013-10-535393","article-title":"Natural history of autoimmune lymphoproliferative syndrome associated with FAS gene mutations","volume":"123","author":"Price","year":"2014","journal-title":"Blood."},{"issue":"5","key":"2021110415300390100_B3","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1586\/1744666X.3.5.813","article-title":"The Wiskott-Aldrich syndrome: from genotype-phenotype correlation to treatment","volume":"3","author":"Moratto","year":"2007","journal-title":"Expert Rev Clin Immunol."},{"issue":"4","key":"2021110415300390100_B4","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1016\/j.jaci.2019.11.051","article-title":"Characterization of the clinical and immunologic phenotype and management of 157 individuals with 56 distinct heterozygous NFKB1 mutations","volume":"146","author":"Lorenzini","year":"2020","journal-title":"J Allergy Clin Immunol."},{"issue":"7814","key":"2021110415300390100_B5","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1038\/s41586-020-2265-1","article-title":"Whole-genome sequencing of a sporadic primary immunodeficiency cohort [correction published in Nature. 2020;584:E2]","volume":"583","author":"Thaventhiran","year":"2020","journal-title":"Nature."},{"issue":"10","key":"2021110415300390100_B6","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.1038\/s41409-019-0516-2","article-title":"Indications for haematopoietic stem cell transplantation for haematological diseases, solid tumours and immune disorders: current practice in Europe, 2019","volume":"54","author":"Duarte","year":"2019","journal-title":"Bone Marrow Transplant."},{"issue":"7","key":"2021110415300390100_B7","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1016\/j.bbmt.2020.03.002","article-title":"Indications for hematopoietic cell transplantation and immune effector cell therapy: guidelines from the American Society for Transplantation and Cellular Therapy","volume":"26","author":"Kanate","year":"2020","journal-title":"Biol Blood Marrow Transplant."},{"issue":"9","key":"2021110415300390100_B8","doi-asserted-by":"crossref","first-page":"2052","DOI":"10.1038\/s41409-021-01378-8","article-title":"EBMT\/ESID inborn errors working party guidelines for hematopoietic stem cell transplantation for inborn errors of immunity","volume":"56","author":"Lankester","year":"2021","journal-title":"Bone Marrow Transplant"},{"issue":"9915","key":"2021110415300390100_B9","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1016\/S0140-6736(13)62069-3","article-title":"Reduced-intensity conditioning and HLA-matched haemopoietic stem-cell transplantation in patients with chronic granulomatous disease: a prospective multicentre study","volume":"383","author":"G\u00fcng\u00f6r","year":"2014","journal-title":"Lancet."},{"issue":"10","key":"2021110415300390100_B10","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1182\/blood.2020005590","article-title":"Hematopoietic cell transplantation in chronic granulomatous disease: a study of 712 children and adults","volume":"136","author":"Chiesa","year":"2020","journal-title":"Blood."},{"issue":"1","key":"2021110415300390100_B11","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1016\/j.jaip.2017.07.045","article-title":"Allogeneic stem cell transplantation in adolescents and young adults with primary immunodeficiencies","volume":"6","author":"Albert","year":"2018","journal-title":"J Allergy Clin Immunol Pract."},{"issue":"8","key":"2021110415300390100_B12","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1182\/blood-2017-09-807487","article-title":"Successful outcome following allogeneic hematopoietic stem cell transplantation in adults with primary immunodeficiency","volume":"131","author":"Fox","year":"2018","journal-title":"Blood."},{"issue":"1","key":"2021110415300390100_B13","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.bbmt.2019.08.018","article-title":"prospective study of a novel, radiation-free, reduced-intensity bone marrow transplantation platform for primary immunodeficiency diseases","volume":"26","author":"Dimitrova","year":"2020","journal-title":"Biol Blood Marrow Transplant."},{"issue":"4","key":"2021110415300390100_B14","doi-asserted-by":"crossref","first-page":"988","DOI":"10.1016\/j.jaci.2014.11.029","article-title":"Multicenter experience in hematopoietic stem cell transplantation for serious complications of common variable immunodeficiency","volume":"135","author":"Wehr","year":"2015","journal-title":"J Allergy Clin Immunol."},{"key":"2021110415300390100_B15","doi-asserted-by":"crossref","first-page":"437","DOI":"10.3389\/fped.2019.00437","article-title":"Allogeneic HSCT in adolescents and young adults with primary immunodeficiencies","volume":"7","author":"Morris","year":"2019","journal-title":"Front Pediatr."},{"issue":"2","key":"2021110415300390100_B16","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1016\/j.jaci.2017.03.049","article-title":"Hematopoietic stem cell transplantation in patients with gain-of-function signal transducer and activator of transcription 1 mutations","volume":"141","author":"Leiding","year":"2018","journal-title":"J Allergy Clin Immunol."},{"issue":"5","key":"2021110415300390100_B17","doi-asserted-by":"crossref","first-page":"1452","DOI":"10.1016\/j.jaci.2019.12.896","article-title":"Long-term outcome of LRBA deficiency in 76 patients after various treatment modalities as evaluated by the immune deficiency and dysregulation activity (IDDA) score","volume":"145","author":"Tesch","year":"2020","journal-title":"J Allergy Clin Immunol."},{"issue":"6","key":"2021110415300390100_B18","doi-asserted-by":"crossref","first-page":"980","DOI":"10.1016\/j.bbmt.2017.03.016","article-title":"Haploidentical related donor hematopoietic stem cell transplantation for dedicator-of-cytokinesis 8 deficiency using post-transplantation cyclophosphamide","volume":"23","author":"Shah","year":"2017","journal-title":"Biol Blood Marrow Transplant."},{"issue":"5","key":"2021110415300390100_B19","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1007\/s12185-016-2062-7","article-title":"Allogeneic hematopoietic stem-cell transplantation for adult and adolescent hemophagocytic lymphohistiocytosis: a single center analysis","volume":"104","author":"Fu","year":"2016","journal-title":"Int J Hematol."},{"issue":"12","key":"2021110415300390100_B20","doi-asserted-by":"crossref","first-page":"1940","DOI":"10.1016\/j.bbmt.2014.08.004","article-title":"Nonmyeloablative allogeneic hematopoietic stem cell transplantation for GATA2 deficiency","volume":"20","author":"Grossman","year":"2014","journal-title":"Biol Blood Marrow Transplant."},{"issue":"6","key":"2021110415300390100_B21","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1182\/blood-2013-07-515528","article-title":"GATA2 deficiency: a protean disorder of hematopoiesis, lymphatics, and immunity","volume":"123","author":"Spinner","year":"2014","journal-title":"Blood."},{"issue":"6","key":"2021110415300390100_B22","doi-asserted-by":"crossref","first-page":"1970","DOI":"10.1016\/j.jaip.2019.02.038","article-title":"Outcomes and treatment strategies for autoimmunity and hyperinflammation in patients with RAG deficiency","volume":"7","author":"Farmer","year":"2019","journal-title":"J Allergy Clin Immunol Pract."},{"issue":"3","key":"2021110415300390100_B23","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1016\/j.jaci.2016.09.040","article-title":"Hematopoietic stem cell transplant in patients with activated PI3K delta syndrome","volume":"139","author":"Nademi","year":"2017","journal-title":"J Allergy Clin Immunol."},{"issue":"1","key":"2021110415300390100_B24","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1007\/s10875-020-00888-2","article-title":"Experience with a reduced toxicity allogeneic transplant regimen for non-CGD primary immune deficiencies requiring myeloablation","volume":"41","author":"Chandra","year":"2021","journal-title":"J Clin Immunol."},{"issue":"6","key":"2021110415300390100_B25","doi-asserted-by":"crossref","first-page":"2238","DOI":"10.1016\/j.jaci.2018.12.1010","article-title":"Hematopoietic stem cell transplantation for CD40 ligand deficiency: results from an EBMT\/ESID-IEWP-SCETIDE-PIDTC study","volume":"143","author":"Ferrua","year":"2019","journal-title":"J Allergy Clin Immunol."},{"key":"2021110415300390100_B26"},{"issue":"6 Pt 1","key":"2021110415300390100_B27","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1016\/S0022-3476(05)82002-5","article-title":"A multiinstitutional survey of the Wiskott-Aldrich syndrome","volume":"125","author":"Sullivan","year":"1994","journal-title":"J Pediatr."},{"issue":"5 Pt 1","key":"2021110415300390100_B28","doi-asserted-by":"crossref","first-page":"e622","DOI":"10.1542\/peds.111.5.e622","article-title":"Autoimmunity in Wiskott-Aldrich syndrome: risk factors, clinical features, and outcome in a single-center cohort of 55 patients","volume":"111","author":"Dupuis-Girod","year":"2003","journal-title":"Pediatrics."},{"issue":"4","key":"2021110415300390100_B29","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1038\/ng0495-414","article-title":"X-linked thrombocytopenia and Wiskott-Aldrich syndrome are allelic diseases with mutations in the WASP gene","volume":"9","author":"Villa","year":"1995","journal-title":"Nat Genet."},{"issue":"2","key":"2021110415300390100_B30","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1182\/blood-2003-05-1480","article-title":"Clinical course of patients with WASP gene mutations","volume":"103","author":"Imai","year":"2004","journal-title":"Blood."},{"issue":"16","key":"2021110415300390100_B31","doi-asserted-by":"crossref","first-page":"3231","DOI":"10.1182\/blood-2009-09-239087","article-title":"X-linked thrombocytopenia (XLT) due to WAS mutations: clinical characteristics, long-term outcome, and treatment options","volume":"115","author":"Albert","year":"2010","journal-title":"Blood."},{"issue":"23","key":"2021110415300390100_B32","doi-asserted-by":"crossref","first-page":"2094","DOI":"10.1182\/blood.2019002939","article-title":"Excellent outcomes following hematopoietic cell transplantation for Wiskott-Aldrich syndrome: a PIDTC report","volume":"135","author":"Burroughs","year":"2020","journal-title":"Blood."},{"issue":"4","key":"2021110415300390100_B33","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1111\/bjh.15831","article-title":"How I manage patients with Wiskott Aldrich syndrome","volume":"185","author":"Rivers","year":"2019","journal-title":"Br J Haematol."},{"issue":"3","key":"2021110415300390100_B34","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1016\/j.jaci.2020.08.034","article-title":"Long-term outcomes for adults with chronic granulomatous disease in the United Kingdom","volume":"147","author":"Campos","year":"2020","journal-title":"J Allergy Clin Immunol."},{"issue":"10","key":"2021110415300390100_B35","doi-asserted-by":"crossref","first-page":"2656","DOI":"10.1182\/blood-2011-06-360313","article-title":"Exome sequencing identifies GATA-2 mutation as the cause of dendritic cell, monocyte, B and NK lymphoid deficiency","volume":"118","author":"Dickinson","year":"2011","journal-title":"Blood."},{"issue":"10","key":"2021110415300390100_B36","doi-asserted-by":"crossref","first-page":"2653","DOI":"10.1182\/blood-2011-05-356352","article-title":"Mutations in GATA2 are associated with the autosomal dominant and sporadic monocytopenia and mycobacterial infection (MonoMAC) syndrome","volume":"118","author":"Hsu","year":"2011","journal-title":"Blood."},{"issue":"8","key":"2021110415300390100_B37","doi-asserted-by":"crossref","first-page":"1278","DOI":"10.3324\/haematol.2017.181909","article-title":"Natural history of GATA2 deficiency in a survey of 79 French and Belgian patients","volume":"103","author":"Donadieu","year":"2018","journal-title":"Haematologica."},{"issue":"6","key":"2021110415300390100_B38","doi-asserted-by":"crossref","first-page":"1250","DOI":"10.1016\/j.bbmt.2018.01.030","article-title":"Allogeneic hematopoietic stem cell transplantation for GATA2 deficiency using a busulfan-based regimen","volume":"24","author":"Parta","year":"2018","journal-title":"Biol Blood Marrow Transplant."},{"issue":"3","key":"2021110415300390100_B39","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1007\/s10875-020-00930-3","article-title":"Inherited GATA2 deficiency is dominant by haploinsufficiency and displays incomplete clinical penetrance","volume":"41","author":"Oleaga-Quintas","year":"2021","journal-title":"J Clin Immunol."},{"issue":"7","key":"2021110415300390100_B40","doi-asserted-by":"crossref","first-page":"1650","DOI":"10.1182\/blood-2011-09-377945","article-title":"Morbidity and mortality in common variable immune deficiency over 4 decades","volume":"119","author":"Resnick","year":"2012","journal-title":"Blood."},{"issue":"2","key":"2021110415300390100_B41","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1182\/blood-2007-11-124545","article-title":"Common variable immunodeficiency disorders: division into distinct clinical phenotypes","volume":"112","author":"Chapel","year":"2008","journal-title":"Blood."},{"key":"2021110415300390100_B42","doi-asserted-by":"crossref","first-page":"220","DOI":"10.3389\/fimmu.2016.00220","article-title":"Genetic diagnosis using whole exome sequencing in common variable immunodeficiency","volume":"7","author":"Maffucci","year":"2016","journal-title":"Front Immunol."},{"issue":"9","key":"2021110415300390100_B43","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1182\/blood.2019000929","article-title":"Current genetic landscape in common variable immune deficiency","volume":"135","author":"Abolhassani","year":"2020","journal-title":"Blood."},{"issue":"6","key":"2021110415300390100_B44","doi-asserted-by":"crossref","first-page":"1675","DOI":"10.1182\/blood-2010-11-319376","article-title":"Long-term outcome and lineage-specific chimerism in 194 patients with Wiskott-Aldrich syndrome treated by hematopoietic cell transplantation in the period 1980-2009: an international collaborative study","volume":"118","author":"Moratto","year":"2011","journal-title":"Blood."},{"issue":"3","key":"2021110415300390100_B45","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1016\/j.jaip.2018.10.035","article-title":"hematopoietic stem cell transplantation as treatment for patients with DOCK8 deficiency","volume":"7","author":"Aydin","year":"2019","journal-title":"J Allergy Clin Immunol Pract."},{"issue":"10","key":"2021110415300390100_B46","doi-asserted-by":"crossref","first-page":"2054","DOI":"10.1016\/j.bbmt.2019.05.031","article-title":"Who is a better donor for recipients of allogeneic hematopoietic cell transplantation: a young HLA-mismatched haploidentical relative or an older fully HLA-matched sibling or unrelated donor?","volume":"25","author":"Karam","year":"2019","journal-title":"Biol Blood Marrow Transplant."},{"issue":"12","key":"2021110415300390100_B47","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1182\/blood.2019001212","article-title":"Selection of unrelated donors and cord blood units for hematopoietic cell transplantation: guidelines from the NMDP\/CIBMTR","volume":"134","author":"Dehn","year":"2019","journal-title":"Blood."},{"key":"2021110415300390100_B48","doi-asserted-by":"crossref","first-page":"552","DOI":"10.3389\/fped.2019.00552","article-title":"Hematopoietic stem cell transplantation for combined immunodeficiencies, on behalf of IEWP-EBMT","volume":"7","author":"Neven","year":"2020","journal-title":"Front Pediatr."},{"issue":"8","key":"2021110415300390100_B49","doi-asserted-by":"crossref","first-page":"1666","DOI":"10.1016\/j.bbmt.2019.04.008","article-title":"Outcomes of related and unrelated donor searches among patients with primary immunodeficiency diseases referred for allogeneic hematopoietic cell transplantation","volume":"25","author":"Acevedo","year":"2019","journal-title":"Biol Blood Marrow Transplant."},{"issue":"5","key":"2021110415300390100_B50","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1016\/j.bbmt.2016.02.001","article-title":"Alternative-donor hematopoietic stem cell transplantation with post-transplantation cyclophosphamide for nonmalignant disorders","volume":"22","author":"Klein","year":"2016","journal-title":"Biol Blood Marrow Transplant."},{"issue":"10","key":"2021110415300390100_B51","doi-asserted-by":"crossref","first-page":"e478","DOI":"10.3324\/haematol.2018.215285","article-title":"T-cell replete haploidentical bone marrow transplantation and post-transplant cyclophosphamide for patients with inborn errors","volume":"104","author":"Kurzay","year":"2019","journal-title":"Haematologica."},{"issue":"7","key":"2021110415300390100_B52","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1016\/j.bbmt.2019.03.009","article-title":"Haploidentical hematopoietic stem cell transplantation with post-transplant cyclophosphamide for primary immunodeficiencies and inherited disorders in children","volume":"25","author":"Neven","year":"2019","journal-title":"Biol Blood Marrow Transplant."},{"key":"2021110415300390100_B53","doi-asserted-by":"crossref","first-page":"434","DOI":"10.3389\/fped.2019.00434","article-title":"Conditioning perspectives for primary immunodeficiency stem cell transplants","volume":"7","author":"Shaw","year":"2019","journal-title":"Front Pediatr."},{"issue":"8","key":"2021110415300390100_B54","doi-asserted-by":"crossref","first-page":"1460","DOI":"10.1016\/j.bbmt.2015.04.009","article-title":"Experience with alemtuzumab, fludarabine, and melphalan reduced-intensity conditioning hematopoietic cell transplantation in patients with nonmalignant diseases reveals good outcomes and that the risk of mixed chimerism depends on underlying disease, stem cell source, and alemtuzumab regimen","volume":"21","author":"Marsh","year":"2015","journal-title":"Biol Blood Marrow Transplant."},{"issue":"1","key":"2021110415300390100_B55","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1182\/blood-2007-03-076679","article-title":"Long-term outcome following hematopoietic stem-cell transplantation in Wiskott-Aldrich syndrome: collaborative study of the European Society for Immunodeficiencies and European Group for Blood and Marrow Transplantation","volume":"111","author":"Ozsahin","year":"2008","journal-title":"Blood."},{"issue":"3","key":"2021110415300390100_B56","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1016\/j.bbmt.2014.11.674","article-title":"Impact of serotherapy on immune reconstitution and survival outcomes after stem cell transplantations in children: thymoglobulin versus alemtuzumab","volume":"21","author":"Willemsen","year":"2015","journal-title":"Biol Blood Marrow Transplant."},{"issue":"5","key":"2021110415300390100_B57","doi-asserted-by":"crossref","first-page":"e194","DOI":"10.1016\/S2352-3026(15)00045-9","article-title":"Association between anti-thymocyte globulin exposure and CD4+ immune reconstitution in paediatric haemopoietic cell transplantation: a multicentre, retrospective pharmacodynamic cohort analysis","volume":"2","author":"Admiraal","year":"2015","journal-title":"Lancet Haematol."},{"key":"2021110415300390100_B58","doi-asserted-by":"crossref","first-page":"315","DOI":"10.3389\/fimmu.2019.00315","article-title":"Differential elimination of anti-thymocyte globulin of fresenius and genzyme impacts T-cell reconstitution after hematopoietic stem cell transplantation","volume":"10","author":"Oostenbrink","year":"2019","journal-title":"Front Immunol."},{"issue":"1","key":"2021110415300390100_B59","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1038\/nrclinonc.2015.128","article-title":"Modern approaches to HLA-haploidentical blood or marrow transplantation [correction published in Nat Rev Clin Oncol. 2016;13:132]","volume":"13","author":"Kanakry","year":"2016","journal-title":"Nat Rev Clin Oncol."},{"issue":"20","key":"2021110415300390100_B60","doi-asserted-by":"crossref","first-page":"1755","DOI":"10.1182\/blood.2019001757","article-title":"Mismatched related vs matched unrelated donors in TCR\u03b1\u03b2\/CD19-depleted HSCT for primary immunodeficiencies","volume":"134","author":"Laberko","year":"2019","journal-title":"Blood."},{"issue":"7","key":"2021110415300390100_B61","doi-asserted-by":"crossref","first-page":"1332","DOI":"10.1016\/j.bbmt.2020.03.018","article-title":"HLA-haploidentical hematopoietic cell transplantation for treatment of nonmalignant diseases using nonmyeloablative conditioning and post-transplant cyclophosphamide","volume":"26","author":"Mallhi","year":"2020","journal-title":"Biol Blood Marrow Transplant."},{"issue":"15","key":"2021110415300390100_B62","doi-asserted-by":"crossref","first-page":"3754","DOI":"10.1182\/bloodadvances.2020002101","article-title":"Stem cell transplantation for children with hemophagocytic lymphohistiocytosis: results from the HLH-2004 study","volume":"4","author":"Bergsten","year":"2020","journal-title":"Blood Adv."},{"issue":"13","key":"2021110415300390100_B63","doi-asserted-by":"crossref","first-page":"1438","DOI":"10.1182\/blood-2018-01-828277","article-title":"Reduced-intensity conditioning for hematopoietic cell transplant for HLH and primary immune deficiencies","volume":"132","author":"Allen","year":"2018","journal-title":"Blood."},{"issue":"23","key":"2021110415300390100_B64","doi-asserted-by":"crossref","first-page":"2638","DOI":"10.1182\/blood.2020006738","article-title":"Extended clinical and immunological phenotype and transplant outcome in CD27 and CD70 deficiency","volume":"136","author":"Ghosh","year":"2020","journal-title":"Blood."},{"issue":"5","key":"2021110415300390100_B65","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1080\/1744666X.2020.1763792","article-title":"Malignancy post-hematopoietic stem cell transplant in patients with primary immunodeficiency","volume":"16","author":"Lum","year":"2020","journal-title":"Expert Rev Clin Immunol."},{"issue":"9","key":"2021110415300390100_B66","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1038\/bmt.2016.113","article-title":"Can we agree on patient-reported outcome measures for assessing hematopoietic cell transplantation patients? A study from the CIBMTR and BMT CTN","volume":"51","author":"Shaw","year":"2016","journal-title":"Bone Marrow Transplant."},{"issue":"2","key":"2021110415300390100_B67","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1016\/j.jaci.2017.02.029","article-title":"Inflammatory and autoimmune manifestations in X-linked carriers of chronic granulomatous disease in the United Kingdom","volume":"140","author":"Battersby","year":"2017","journal-title":"J Allergy Clin Immunol."},{"issue":"1","key":"2021110415300390100_B68","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1016\/j.jaci.2017.04.035","article-title":"X-linked carriers of chronic granulomatous disease: Illness, lyonization, and stability","volume":"141","author":"Marciano","year":"2018","journal-title":"J Allergy Clin Immunol."},{"issue":"1","key":"2021110415300390100_B69","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1093\/ecco-jcc\/jjv186","article-title":"Diagnostic and treatment options for severe IBD in female X-CGD carriers with non-random X-inactivation","volume":"10","author":"Hauck","year":"2016","journal-title":"J Crohn\u2019s Colitis"},{"issue":"11","key":"2021110415300390100_B70","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1182\/blood-2017-04-777136","article-title":"Gene therapy for Wiskott-Aldrich syndrome in a severely affected adult","volume":"130","author":"Morris","year":"2017","journal-title":"Blood."},{"issue":"5","key":"2021110415300390100_B71","doi-asserted-by":"crossref","first-page":"e239","DOI":"10.1016\/S2352-3026(19)30021-3","article-title":"Lentiviral haemopoietic stem\/progenitor cell gene therapy for treatment of Wiskott-Aldrich syndrome: interim results of a non-randomised, open-label, phase 1\/2 clinical study","volume":"6","author":"Ferrua","year":"2019","journal-title":"Lancet Haematol."},{"issue":"2","key":"2021110415300390100_B72","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1038\/s41591-019-0735-5","article-title":"Lentiviral gene therapy for X-linked chronic granulomatous disease","volume":"26","author":"Kohn","year":"2020","journal-title":"Nat Med."}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/blood\/article-pdf\/138\/18\/1666\/1832881\/bloodbld2020008187c.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/blood\/article-pdf\/138\/18\/1666\/1832881\/bloodbld2020008187c.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,11,4]],"date-time":"2021-11-04T15:30:47Z","timestamp":1636039847000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/138\/18\/1666\/476054\/How-I-use-allogeneic-HSCT-for-adults-with-inborn"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11,4]]},"references-count":72,"journal-issue":{"issue":"18","published-print":{"date-parts":[[2021,11,4]]}},"URL":"https:\/\/doi.org\/10.1182\/blood.2020008187","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,11,4]]}}}